NewAmsterdam Pharma Company N.V.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2022 | $48.4M | $478.5M | — |
| FY2023 | $58.7M | $347.1M | $340.5M |
| FY2024 | $107.1M | $864.6M | $771.7M |
| FY2025 | $85.9M | $769.3M | $490.0M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2022 | $48.4M | $478.5M | — |
| FY2023 | $58.7M | $347.1M | $340.5M |
| FY2024 | $107.1M | $864.6M | $771.7M |
| FY2025 | $85.9M | $769.3M | $490.0M |